MedTrace Logo

Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

NCT01846351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2013-05-03

No results posted yet for this study

Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Conditions

  • Epiretinal Membrane
  • Age Related Macular Degeneration

Sponsors & Collaborators

  • New England Retina Associates

    lead OTHER

Principal Investigators

  • Nauman A Chaudhry, MD · New England Retina Associates

  • Peter E Liggett, MD · New England Retina Associates

Eligibility

Min Age
58 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846351 on ClinicalTrials.gov